Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial - Wikidata - wikimedia - TriplyDB

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

http://www.wikidata.org/entity/Q33956059

about

Fifty years of melphalan use in hematopoietic stem cell transplantation Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6 A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.Arsenic trioxide - An old drug rediscovered.Review of high-dose intravenous vitamin C as an anticancer agent.Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.Development of target-specific treatments in multiple myeloma.Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors.New developments in conditioning regimens before auto-SCT in multiple myeloma.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Not too little, not too much-just right! (Better ways to give high dose melphalan).Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.As(2)O (3) oxidation by vitamin C: cell culture studies.Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on hum Induction of cellular and molecular Immunomodulatory pathways by vitamin E and vitamin C.Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

P2860

Q26824498-041D6FF0-626E-4209-A2A9-7C4FD48E5E53 Q28395254-D1E1E6B7-DA23-4A44-8E6F-837DF26719F8 Q28481142-1E15E362-C888-4005-AEBA-855830575AC8 Q33586505-4902815C-D485-4B8A-8483-3CC67FBDC278 Q33956039-56860D81-290B-488F-AA6A-15C2278DC045 Q34054167-6E110939-A2C1-4B54-A65C-93D6FB26A7EB Q34406887-75DE6C29-BB2E-4F99-BDC9-BA792D52FAE2 Q37486703-29A567A7-AEB6-4979-9602-A07682C3B68C Q37544427-1E7188AE-92C6-4D7D-A341-4CD5263B962F Q37771370-E301C06F-C334-4D36-8759-0AB48CE8A0E8 Q37845832-0ADBDA2C-D13B-4E8B-89A8-77EE476C3AD7 Q37848037-55340A34-3A3F-4621-901A-65179DF9047B Q38095526-699BB2AF-3167-47BE-A360-8CECBE01D912 Q38240941-4D438972-54E7-407A-84B9-095B2EE2447B Q38253354-E91A7829-5FC3-493E-A38F-A1DC617AE0AA Q39493615-79AC98F7-692A-4876-B694-5BA9FB70BBC1 Q39552261-E8713029-05F1-4DD5-938C-67FB37B23B7F Q40047014-9A6034B3-3C15-415C-92D2-6F1E30325453 Q42009130-B0A7E4FD-49F6-4D63-9608-5A24D7BC674F Q47238436-92919DD0-7F26-41F2-B130-C5286F0A6AC1 Q47630577-6431067F-CC39-49ED-9F79-A8ED0EA93DD1

P2860

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

http://www.wikidata.org/entity/Q33956059

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@ast

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@en

type

label

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@ast

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@en

prefLabel

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@ast

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@en

P1433

Q33956059-584E3226-6763-47F9-BE89-28EAA68CC3B4

P1476

Q33956059-333CF9E7-985D-4945-AE3E-0D866FA6AE2E

P2093

Q33956059-16E7B42D-88DD-42A7-BAFC-410966B69466

Q33956059-2803D7BA-729A-420F-A1EE-FA2A443C809D

Q33956059-2F409579-9C02-4791-9F0F-2519F9AA612D

Q33956059-3891E772-AC3E-4BE7-9005-2D3F47DF8406

Q33956059-38F67015-6A0A-46DA-BC26-C08BEDF7BBCC

Q33956059-38FC46BA-11F1-428A-8B0D-295E893843F4

Q33956059-39968331-B1DC-4010-B0FE-4160866138C6

Q33956059-3A617BE7-FB6A-4490-AC66-0C8C19091920

Q33956059-4659522C-C076-4197-AFFD-681046553AAD

Q33956059-4F5BA13E-1460-4393-9536-1DC6CC9C1543

P2860

Q33956059-0937378A-0FE9-426C-B3E6-0D25249E608D

Q33956059-0C1620A9-C7A6-49DE-B967-A96792AE30FB

Q33956059-0DBD58E5-95CD-4071-AE1F-3354EF6D61CD

Q33956059-14FC7E6A-5C05-4C9C-8912-65C018468B21

Q33956059-15C921E0-1628-46A2-95EC-2B7BBF52BD35

Q33956059-1E359666-5645-4EE9-9AE9-F861473C0722

Q33956059-209FCE7F-85AE-4C07-ADB7-58E77E06D8E9

Q33956059-2B2D0629-A67B-46C7-A2A8-476DBBCD8E7C

Q33956059-3A813858-61B1-4D63-9817-F8DE01481D90

Q33956059-45C53D77-31D9-4885-97FC-4C7E24116971

P304

Q33956059-CAF41FB8-C8E1-452D-B4D6-2E6B77612A74

P31

Q33956059-18FED7CA-BE93-47C7-9B83-0A4A563E85ED

P356

Q33956059-4C113200-E2F8-43B3-A2BF-C9DDFEEC3BC3

P433

Q33956059-D0CE9169-99D8-4BB7-A6E8-5E9DA5A3D592

P478

Q33956059-68801AA9-9987-4C0A-BE99-AD796B3CD11B

P50

Q33956059-4F15893E-443D-4A6D-AC6E-B6DB119CD7F4

P577

Q33956059-E71E6331-B250-42A3-86C9-640978573A77

P698

Q33956059-F76DF3C7-D380-4E47-A921-3B24F51A668D

P921

Q33956059-1330C4B0-BF17-4A74-B264-AEB1ACF77399

P932

Q33956059-0FDF54D8-BCF7-45F0-BDBA-4C26C9079772

P356

J.BBMT.2008.09.019

P1433

Biology of Blood and Marrow Transplantation

P1476

Arsenic trioxide with ascorbic ...... of a phase II randomized trial

@en

P2093

Amin Alousi

http://www.w3.org/2001/XMLSchema#string

Chitra Hosing

http://www.w3.org/2001/XMLSchema#string

Donna M Weber

http://www.w3.org/2001/XMLSchema#string

Fatima B Khan

http://www.w3.org/2001/XMLSchema#string

Floralyn Mendoza

http://www.w3.org/2001/XMLSchema#string

Gaurav Parikh

http://www.w3.org/2001/XMLSchema#string

Matteo Pelosini

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Muzaffar H Qazilbash

http://www.w3.org/2001/XMLSchema#string

Paolo Anderlini

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma.

Multiple myeloma.

P304

1401-1407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2008.09.019

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19041063

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4112362

http://www.w3.org/2001/XMLSchema#string